GSK Receives Approval for Arexvy as the First RSV Vaccine for Older Adults

GSK has received approval from Japan's Ministry of Health, Labour, and Welfare (MHLW) for Arexvy, a recombinant adjuvanted vaccine designed to protect adults aged 60 years and older from respiratory syncytial virus (RSV) disease.

This milestone marks the first approval of an RSV vaccine for older adults in Japan and has the potential to benefit around 43.5 million individuals in this age group. This approval follows similar authorisations granted earlier this year in the United States, the European Union, the United Kingdom, and Canada.

RSV is a contagious virus that primarily affects the respiratory system, posing a significantly increased risk of severe illness in older adults. RSV can exacerbate pre-existing health conditions such as COPD, asthma, and chronic heart failure, often leading to serious complications like pneumonia, hospitalisation, and even mortality.

Annually, RSV leads to over 470,000 hospitalisations and approximately 33,000 in-hospital deaths among individuals aged 60 and above in developed countries. In Japan alone, this translates to roughly 63,000 hospitalisations and 4,500 fatalities. Adults with underlying medical conditions are more susceptible to seeking medical care and experiencing higher hospitalisation rates compared to those without such conditions.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!